enVVeno Medical Corp (NVNO)
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
enVVeno Medical Corporation
- 3.5%
- 24.1K
- 1.00
Float 690.75K · Signal8 dilution snapshot · Oct 29, 2026
The cost to borrow NVNO shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 11.1%
- 206
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 24.1K sh |
| Oct 15, 2026 | 11.8K sh |
| Sep 30, 2026 | 13.5K sh |
| Sep 15, 2026 | 9.4K sh |
| Aug 31, 2026 | 8.4K sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 30, 2026 | 206 sh |
| Sep 3, 2026 | 46 sh |
| Jul 1, 2026 | 2 sh |
| Apr 23, 2026 | 23 sh |
| Apr 17, 2026 | 2 sh |
A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 17, 2026 | 11.1% |
| Nov 16, 2026 | 19.2% |
| Nov 13, 2026 | 44.8% |
| Nov 12, 2026 | 70.8% |
| Nov 11, 2026 | 31.7% |
130 calendar days requested; 92 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for NVNO: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 24,103 NVNO shares were sold short (3.49% of a 691K-share float, 1.00 days to cover).